Theravance Biopharma Announces Merger with Zymeworks; Supplemental Proxy Disclosures

What Happened
Theravance Biopharma (filed 8‑K on Sep 10, 2026) announced supplemental disclosures to the definitive proxy (filed Aug 21, 2026) for its previously announced Merger Agreement with Zymeworks (Merger Agreement dated June 28, 2026). The company confirmed the extraordinary general meeting of shareholders to vote on the Merger will be held on September 18, 2026 at 1:30 p.m. PT. Theravance said it is supplementing the proxy to provide additional background and factual detail after receiving litigation and shareholder demand letters related to the transaction; it denies the allegations and says no supplemental disclosure is legally required but is providing these updates to minimize disruption.

Key Details

• Merger background: Merger Agreement dated June 28, 2026; after the Merger Merger Sub will merge into Theravance, with Theravance surviving as a wholly owned subsidiary of Zymeworks. Shareholder vote scheduled for Sep 18, 2026.
• Litigation & demands: As of Sep 10, 2026, three complaints were filed (Richardson v. Theravance (N.Y. Sup. Ct. Aug. 25, 2026), Thompson v. Theravance (N.Y. Sup. Ct. Aug. 26, 2026), Maglione v. Susannah Gray (Cal. Super. Ct. Sep. 2, 2026)) and the company received 13 demand letters alleging proxy disclosure deficiencies. Plaintiffs seek injunctions, rescission and/or damages; Theravance and other defendants deny the allegations.
• Valuation inputs disclosed: Lazard’s analysis used June 30, 2026 net debt of approximately $(385) million and ~54.9 million fully diluted ordinary shares (treasury stock method) and implied an equity value range of $15.25 to $16.25 per ordinary share.
• Other updates: Evercore engagement amended to provide a $7.0 million fee upon consummation of the Merger; the proxy was updated with expanded background about outreach (e.g., outreach to ~60 counterparties, 20 confidentiality agreements, 12 parties conducted limited due diligence) and clarifications on standstill terms. The proxy also states that Parent and Theravance management had not discussed specific post‑closing employment or equity participation terms as of the proxy date.

Why It Matters
These supplemental disclosures affect shareholders by (1) providing more detail on the sale process and third‑party outreach that informed the board’s decision, (2) laying out Lazard’s valuation inputs and an implied per‑share equity range that investors can use to assess the deal, and (3) documenting pending litigation and demand letters that could seek to delay or alter the Merger. Theravance says the claims lack merit but is supplementing the proxy to reduce the risk of delay and provide shareholders with additional information ahead of the Sep 18 vote. Investors should review the definitive proxy (filed Aug 21, 2026) and this 8‑K supplement for details before voting.